Table 10. Major Characteristics of Sixty-one Single Arm Researches on Peritoneal Carcinomatosis (PC) from Colorectal Cancer (CRC) Treated with Cytoreductive Surgery (CRS) plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
| Author/ Years/ Country | Participating Institutions |
Study Period | Design | Level of evidence | Number of CRC PC | HIPEC |
|---|---|---|---|---|---|---|
| Tabrizian/ 2014/ America [78] | 1 | 2007-2012 | retrospective | III | 51 (51/170) | MMC (total dose 40 mg) for 90 min at 41-43 °C using closed abdomen technique. |
| Teo/ 2013/ Singapore [79] |
1 | 2001-2012 | retrospective | III | 28 (28/100) | MMC for 60 min at 42 °C using closed abdomen technique. |
| Teo/ 2014/ Singapore [80] |
1 | 2001-2012 | retrospective | III | 35 (35/35) | MMC for 60 min at 42 °C using closed abdomen technique. |
| Ung/ 2013/ Australia [81] |
1 | 2000-2012 | retrospective | III | 125 (125/211) | MMC (12.5 mg/m2) for 90 min at 42 °C using coliseum technique. |
| Vaira/ 2010/ Italy [82] | 1 | 2002-2008 | retrospective | III | 40 (40/72) | MMC (16 mg/m2) + DDP (100 mg/m2) for 60 min at 41.5 °C using semi-closed abdomen technique. Before HIPEC, LV (20 mg/m2) and 5-FU (400 mg/m2) were delivered by systemic i.v. L-OHP (460 mg/m2) for 30 min at 42 °C using semi-closed abdomen technique. |
| van Leeuwen / 2008/ Sweden [83] | 1 | 2003-2006 | retrospective | III | 38 (38/103) | Before HIPEC, LV (30 mg/m2) and 5-FU (500 mg/m2) were delivered by systemic i.v. HIPEC: L-OHP (460 mg/m2) for 30 min at 42-44 °C using the coliseum technique. |
| van Oudheusden/ 2014/ Netherlands [84] | 2 | 2005-2013 | retrospective | III | 113 (113/149) | MMC (35 mg/m2) for 90 min at 41-42 °C using coliseum technique. |
| van Oudheusden / 2015/ Netherlands [85] | 2 | 2005-2013 | retrospective | III | 252 (252/351) | MMC (35 mg/m2) for 90 min at 41.1 °C using open-coliseum technique. |
| Varban/ 2009/ America [86] |
1 | 1991-2007 | retrospective | III | 128 (128/142) | MMC (total dose 30 mg) for 60 or 90 min at 42.5 °C using closed abdomen technique. MMC (total dose 40 mg) for 120 min at 42.5 °C using closed abdomen technique. |
| Verwaal/ 2005/ Netherlands [19] | 1 | 1995-2003 | retrospective | III | 117 (117/117) | MMC (35 mg/m2) for 90 min at 40-41 °C using coliseum technique. |
| Votanopoulos/ 2013/ America [87] | 1 | 1993-2011 | retrospective | III | 217 (217/217) | MMC for 90-120 min at 40.5-43 °C using closed abdomen technique. |
| Winer/ 2014/ America [88] |
1 | 2001-2011 | retrospective | III | 30 (30/67) | MMC (total dose 40 mg) for 100 min at 42 °C using closed abdomen technique. |
| Witkamp/ 2001/ Netherlands [89] | 1 | 1995-1997 | prospective | IIb | 29 (29/29) | MMC (15-40 mg/m2 initially; 35 mg/m2 majority) for 90 min at 40-41 °C using closed abdomen technique. |
| Yan/ 2006/ Australia [90] |
1 | 1997-2006 | prospective | IIb | 30 (30/30) | MMC (10-12.5 mg/m2) for 90 min at 42 °C using coliseum technique. |
| Yan/ 2008/ Australia [91] |
1 | 1997-2007 | retrospective | III | 50 (50/50) | MMC (10-12.5 mg/m2) for 90 min at 42 °C using coliseum technique. |
| Zanon/ 2006/ Italy [92] | 1 | 1998-2004 | prospective | III | 25 (25/25) | MMC (15 mg/m2) for 60 min at 42 °C using closed abdomen technique. |
Note: MMC: mitomycin C; DDP: cisplatin; FU: fluorouracil; LV: leucovorin; L-OHP: oxaliplatin; CPT-11: irinotecan; NR: not reported